<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00730314</url>
  </required_header>
  <id_info>
    <org_study_id>CCI #07-00119</org_study_id>
    <secondary_id>CHLA-#07-00119</secondary_id>
    <nct_id>NCT00730314</nct_id>
  </id_info>
  <brief_title>Unrelated Hematopoietic Stem Cell Transplantation(HSCT) for Genetic Diseases of Blood Cells</brief_title>
  <official_title>Phase I/II Trial Of Hematopoietic Stem Cell Transplant (HSCT) For Children With A Genetic Disease Of Blood Cells Without An HLA-Matched Sibling Donor</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Children's Hospital Los Angeles</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Children's Hospital Los Angeles</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a clinical trial of bone marrow transplantation for patients with the diagnosis of a&#xD;
      genetic disease of blood cells that do not have an HLA-matched sibling donor. Genetic&#xD;
      diseases of blood cell include: Red blood cell defects e.g. hemoglobinopathies (sickle cell&#xD;
      disease and thalassemia), Blackfan-Diamond anemia and congenital or chronic hemolytic&#xD;
      anemias; White blood cells defects/immune deficiencies e.g. chronic granulomatous disease,&#xD;
      Wiskott-Aldrich syndrome,Osteopetrosis, Kostmann's syndrome (congenital neutropenia),&#xD;
      Hereditary Lymphohistiocytosis (HLH); Platelets defects e.g.Congenital amegakaryocytic&#xD;
      thrombocytopenia; Metabolic/storage disorders e.g. leukodystrophies,mucopolysaccharidoses as&#xD;
      Hurler disease;Stem cell defects e.g.reticular agenesis, among many other rare similar&#xD;
      conditions.&#xD;
&#xD;
      The study treatment plan uses a new transplant treatment regimen that aims to try to decrease&#xD;
      the acute toxicities and complications associated with the standard treatment plans and to&#xD;
      improve outcome&#xD;
&#xD;
      The blood stem cells will be derived from either unrelated donor or unrelated umbilical cord&#xD;
      blood.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a pilot clinical trial of hematopoietic stem cell transplantation for patients with&#xD;
      the diagnosis of a genetic disease of blood cells that do not have an HLA-matched sibling&#xD;
      donor. The stem cells will be derived from a 1) matched unrelated donor (MUD) or 2) unrelated&#xD;
      umbilical cord blood (UCB). Patients will receive a novel conditioning regimen with Busulfan,&#xD;
      Cytoxan and Fludarabine (Bu/Cy/Flu) and either Alemtuzumab (Campath 1H) for recipients of a&#xD;
      MUD or rabbit Antithymocyte Globulin (rATG) for recipients of unrelated UCB prior to&#xD;
      hematopoietic stem cell transplant (HSCT).&#xD;
&#xD;
      It is hypothesized that reduced dosages of Cytoxan will decrease the acute toxicities&#xD;
      associated with the standard chemotherapies of Busulfan and Cytoxan (i.e. sinusoidal&#xD;
      obstructive syndrome (SOS), hemorrhagic cystitis and mucositis). And the addition of&#xD;
      fludarabine to a conditioning regimen with myeloablative doses of Busulfan and reduced&#xD;
      dosages of Cytoxan prior to HSCT will overcome the engraftment barrier posed by an intact&#xD;
      immune system, which is seen in patients with a genetic disease.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>August 2008</start_date>
  <completion_date type="Actual">August 2015</completion_date>
  <primary_completion_date type="Actual">August 2015</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>toxicities</measure>
    <time_frame>3 years</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>adverse events</measure>
    <time_frame>3 years</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>engraftment</measure>
    <time_frame>1 year</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>immune reconstitution</measure>
    <time_frame>3 years</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>overall and event free survival survival</measure>
    <time_frame>3 years</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">25</enrollment>
  <condition>Sickle Cell Disease</condition>
  <condition>Thalassemia</condition>
  <condition>Anemia</condition>
  <condition>Granuloma</condition>
  <condition>Wiskott-Aldrich Syndrome</condition>
  <condition>Chediak Higashi Syndrome</condition>
  <condition>Osteopetrosis</condition>
  <condition>Neutropenia</condition>
  <condition>Thrombocytopenia</condition>
  <condition>Hurler Disease</condition>
  <condition>Niemann-Pick Disease</condition>
  <condition>Fucosidosis</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Unrelated donor</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Cord Blood</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Hematopoietic stem cell transplantation</intervention_name>
    <description>hematopoietic stem cell transplantation conditioning regimen depending on graft source</description>
    <arm_group_label>1</arm_group_label>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Lethal or sublethal genetic disease of blood cells, who lack a fully histocompatible&#xD;
             sibling or other family donor&#xD;
&#xD;
          -  Genetic diseases that would be candidates for this protocol includes those that have&#xD;
             been shown to benefit from allogeneic HSCT: Red blood cell defects, Leukocyte defects/&#xD;
             Primary immune deficiencies, Platelets defects, Metabolic/storage disorders and Stem&#xD;
             cell defects.&#xD;
&#xD;
          -  Renal: creatinine clearance or glomerular filtration rate (GFR) ≥50 ml/min/1.73m2 and&#xD;
             not requiring dialysis.&#xD;
&#xD;
          -  Pulmonary: FEV1, FVC and DLCO (corrected for hemoglobin) ≥ 50% predicted. if unable to&#xD;
             perform pulmonary function tests, then O2 saturation ≥ 92% in room air.&#xD;
&#xD;
          -  Cardiac: Left ventricular ejection fraction at rest must be ≥ 40%, or shortening&#xD;
             fraction ≥ 26%&#xD;
&#xD;
          -  Hepatic: Bilirubin ≤3x upper limit of normal (ULN) and ALT and AST ≤ 5x for age (with&#xD;
             the exception of isolated hyperbilirubinemia due to Gilbert's syndrome).&#xD;
&#xD;
          -  Patients will be 0-21 years of age.&#xD;
&#xD;
          -  Disease specific inclusion criteria (as applicable per protocol).&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Recipients should not have any of the general exclusion criteria, and disease specific&#xD;
             exclusion criteria when applicable.&#xD;
&#xD;
          -  Patient with histocompatible sibling&#xD;
&#xD;
          -  End-organ failure that precludes the ability to tolerate the transplant procedure,&#xD;
             including the conditioning regimen.&#xD;
&#xD;
          -  Creatinine clearance or GFR &lt; 50 ml/min/1.73m2 or renal failure requiring dialysis.&#xD;
&#xD;
          -  Congenital heart disease resulting in congestive heart failure.&#xD;
&#xD;
          -  Severe residual CNS disease/impairment [(other than hemiplegia alone) e.g. coma or&#xD;
             intractable seizures]&#xD;
&#xD;
          -  Ventilatory failure&#xD;
&#xD;
          -  Major congenital anomalies that adversely affect survival, e.g. CNS malformations&#xD;
&#xD;
          -  Lansky score &lt; 40% or Karnofsky score &lt; 60%&#xD;
&#xD;
          -  HIV seropositivity&#xD;
&#xD;
          -  Diagnosis of Fanconi's anemia, Severe Combined Immunodeficiency (SCID)&#xD;
&#xD;
          -  Positive pregnancy test (For female patients in child bearing period)&#xD;
&#xD;
          -  Uncontrolled bacterial, viral, or fungal infections (currently taking medication yet&#xD;
             clinical symptoms progress)&#xD;
&#xD;
          -  Disease specific exclusion criteria (as applicable per protocol).&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>21 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Hisham Abdel-Azim, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Childrens Hospital Los Angeles, University of Southern California</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Children Hospital Los Angeles</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90027</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.childrenshospitalla.org</url>
    <description>Related Info</description>
  </link>
  <verification_date>June 2016</verification_date>
  <study_first_submitted>August 6, 2008</study_first_submitted>
  <study_first_submitted_qc>August 7, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 8, 2008</study_first_posted>
  <last_update_submitted>June 21, 2016</last_update_submitted>
  <last_update_submitted_qc>June 21, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 23, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Children's Hospital Los Angeles</investigator_affiliation>
    <investigator_full_name>Hisham Abdel-Azim</investigator_full_name>
    <investigator_title>Principle Investigator</investigator_title>
  </responsible_party>
  <keyword>unrelated</keyword>
  <keyword>BMT</keyword>
  <keyword>HSCT</keyword>
  <keyword>bone marrow transplantation</keyword>
  <keyword>sickle cell disease</keyword>
  <keyword>thalassemia</keyword>
  <keyword>CGD</keyword>
  <keyword>HLH</keyword>
  <keyword>Blackfan-Diamond anemia</keyword>
  <keyword>Hurler</keyword>
  <keyword>leukodystrophy</keyword>
  <keyword>LAD I</keyword>
  <keyword>Genetic diseases</keyword>
  <keyword>Red blood cell defects</keyword>
  <keyword>Leukocyte defects and immune deficiencies</keyword>
  <keyword>Hereditary Lymphohistiocytosis</keyword>
  <keyword>chronic granulomatous disease</keyword>
  <keyword>Wiskott-Aldrich syndrome</keyword>
  <keyword>Chediak Higashi syndrome</keyword>
  <keyword>CD40 ligand deficiency</keyword>
  <keyword>Hyper IgM syndrome</keyword>
  <keyword>leucocytes adhesion defect type 1</keyword>
  <keyword>Osteopetrosis</keyword>
  <keyword>congenital neutropenia</keyword>
  <keyword>X-linked lymphoproliferative disease</keyword>
  <keyword>Platelets defects</keyword>
  <keyword>Congenital amegakaryocytic thrombocytopenia</keyword>
  <keyword>Metabolic and storage disorders</keyword>
  <keyword>Hurler disease</keyword>
  <keyword>leukodystrophies</keyword>
  <keyword>Niemann-Pick disease</keyword>
  <keyword>Fucosidosis</keyword>
  <keyword>Stem cell defects</keyword>
  <keyword>reticular agenesis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Osteopetrosis</mesh_term>
    <mesh_term>Pick Disease of the Brain</mesh_term>
    <mesh_term>Aphasia, Primary Progressive</mesh_term>
    <mesh_term>Frontotemporal Dementia</mesh_term>
    <mesh_term>Niemann-Pick Diseases</mesh_term>
    <mesh_term>Niemann-Pick Disease, Type A</mesh_term>
    <mesh_term>Niemann-Pick Disease, Type C</mesh_term>
    <mesh_term>Fucosidosis</mesh_term>
    <mesh_term>Chediak-Higashi Syndrome</mesh_term>
    <mesh_term>Anemia, Sickle Cell</mesh_term>
    <mesh_term>Thrombocytopenia</mesh_term>
    <mesh_term>Thalassemia</mesh_term>
    <mesh_term>Neutropenia</mesh_term>
    <mesh_term>Granuloma</mesh_term>
    <mesh_term>Wiskott-Aldrich Syndrome</mesh_term>
    <mesh_term>Genetic Diseases, Inborn</mesh_term>
    <mesh_term>Mucopolysaccharidosis I</mesh_term>
    <mesh_term>Syndrome</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

